Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STATIC: intermittent versus continuous BTK inhibitor treatment in chronic lymphocytic leukaemia
ISRCTN51675454Phase 3Recruiting
- Sponsor
- University of Leeds
- Start
- Oct 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ibrutinib and acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by University of Leeds. Started Oct 2022; status: recruiting.
02
Drugs
ibrutinibacalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ISRCTN51675454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN51675454.